Format

Send to

Choose Destination
Ann Oncol. 2019 Mar 26. pii: mdz109. doi: 10.1093/annonc/mdz109. [Epub ahead of print]

How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.

Author information

1
University of Lausanne, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
2
Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center of Lung Research (DZL), Grosshansdorf, Germany.
3
Department of Pulmonary Diseases, VU University Medical Centre, Amsterdam, Netherlands.
4
Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
5
Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
6
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, and Parker Center for Cancer Immunotherapy, New York, NY, USA.

Abstract

Antibodies that target programmed death 1 (PD-1) or its ligand (programmed death ligand 1 (PD-L1) have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC) without targetable genetic alterations. In this review, we summarize results from recent clinical trials that have evaluated the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies atezolizumab and durvalumab as first-line treatment as monotherapy, in combination with chemotherapy, other immunotherapies, and anti-angiogenesis agents. We discuss factors that may influence treatment selection, including patient baseline clinical and demographic characteristics, tumor histology, and biomarkers such as PD-L1 expression and tumor mutation burden. While immunotherapy has become a central component of first-line treatment for most patients with advanced NSCLC, important questions remain about how treatment should be managed for individual patients.

KEYWORDS:

atezolizumab; durvalumab; first-line; immunotherapy; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab

PMID:
30912805
DOI:
10.1093/annonc/mdz109

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center